ArticleMayo Clinic proceedings. Digital health2026
Evaluation of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Incidental Pulmonary Nodules: The CREATE Study.
Article in Mayo Clinic proceedings. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05817110 (Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule Multicentric, Multinational, Prospective, Observational Study.), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Realworld Cohort Study to Validate Effectiveness of an Artificial Intelligence Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule Multicentric, Multinational, Prospective, Observational Study.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effectiveness of the artificial intelligence-based qXR lung nodule malignancy score (qXR-LNMS) in detecting high-risk incidental pulmonary nodules (IPNs) on chest X-rays (CXRs). Patients and Methods: The CREATE (NCT05817110), a prospective, observational study for participants aged 35 years or older with IPN (size, ≥8 to ≤30 mm) on CXR, enrolled 712 participants (high-risk: 498 and low-risk: 214) between April 1, 2023, and December 31, 2024. Participants were flagged by the Food and Drug Administration-cleared qXR detection algorithm and confirmed by radiologists. Threshold for success was set at 20% for positive predictive value (PPV) and 70% for negative predictive value (NPV). The primary and secondary outcomes included PPV and NPV of qXR-LNMS against the risk of malignancy assessed by radiologists using low-dose computed tomography (LDCT) and binarized risk categories based on Lung-RADS score and Mayo Clinic model and PPVs and NPVs by clinicodemographic characteristics with 95% CIs using Wilson score method. Results: Overall, the PPV and the NPV of qXR-LNMS risk prediction against radiologists' assessment on LDCT were 54.2% (95% CI, 49.8-58.5) and 93.5% (95% CI, 89.3-96.1), respectively. The agreement between Mayo Clinic model and qXR-LNMS was observed in 70.6% participants (Spearman correlation, 0.247). Results across key subgroups were consistent with all PPV and NPV point estimates crossing the prespecified threshold. Conclusion: The results demonstrate the potential of qXR-LNMS in predicting benign and malignant IPN on CXR, thereby supporting lung cancer screening, particularly in resource-limited settings, although further validation is needed. Trials Registration: clinicaltrials.gov Identifier: NCT05817110.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.